Last Updated: November 8, 2026

AVGEMSI Drug Patent Profile

Name: AVGEMSI Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which patents cover Avgemsi, and what generic alternatives are available?

Avgemsi is a drug marketed by Avyxa Holdings and is included in one NDA.

The generic ingredient in AVGEMSI is gemcitabine hydrochloride. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the gemcitabine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Avgemsi

A generic version of AVGEMSI was approved as gemcitabine hydrochloride by HOSPIRA INC on November 15^th, 2010.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for AVGEMSI?
What are the global sales for AVGEMSI?
What is Average Wholesale Price for AVGEMSI?

Summary for AVGEMSI

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	6,217
What excipients (inactive ingredients) are in AVGEMSI?	AVGEMSI excipients list
DailyMed Link:	AVGEMSI at DailyMed

Drug patent expirations by year for AVGEMSI

Pharmacology for AVGEMSI

Drug Class	Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors

US Patents and Regulatory Information for AVGEMSI

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avyxa Holdings	AVGEMSI	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	219920-002	Jun 27, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Avyxa Holdings	AVGEMSI	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	219920-003	Jun 27, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Avyxa Holdings	AVGEMSI	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	219920-001	Jun 27, 2025		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.